Evaluation of Liquorice Nanogel Versus Diode Laser as an Adjunctive Treatment for Patients With Periodontitis Stage Ⅲ. (Periodontology)

May 19, 2026 updated by: Alaa Yousri Mohamed, Al-Azhar University
Evaluation of the effect of liquorice nanogel versus diode laser on periodontitis stage Ⅲ clinically and microbiologically by molecular analysis of porphyromonas gingivalis using real time PCR.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Quantitative analysis technique using real time pcr (polymerase chain reaction) was done to detect presence of porphyromonas gingivalis. Pocket depth (PD), Plaque index (PI), gingival index (GI) and Clinical attachment level (CAL) were measured before work and after 3 months postoperatively.

Analysis was made from gingival crevicular fluid samples of the patients using gutta percha paper points.

Study Type

Interventional

Enrollment (Actual)

27

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
    • Cairo Governorate
      • Cairo, Cairo Governorate, Egypt, 00202
        • Alazhar University for Girls

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Patient had Periodontitis stage III with pocket depth ≥ 6mm; indicated for periodontal surgery or CAL ≥ 5mm.
  2. Patient agreed to the surgical procedure and clinical trial.
  3. Age ranged between 18-50 years old.

Exclusion Criteria:

  • 1: No previous drug was taken affecting bone metabolism. 2- Smoking. 3- Pregnant women and women with menopause. 4- Patients with psychological problems . 5- Patients with abnormal habits. 6- Patients with medical conditions as Diabetes or Hypertension.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: control group
no drug was added to control group
Drug: Liquorice Nanogel
Real Time pcr was chosen to detect 16s gene concentration for porphyromonas gingivalis bacteria that is specific for Periodontitis Stage 3.
Drug: diode laser
Real time Pcr was used to detect gene concentration 16s specific for porphyromonas gingivalis
Experimental: Liquorice Nanogel
10% Liquorice was prepared in nanogel concentrate
Drug: Liquorice Nanogel
Real Time pcr was chosen to detect 16s gene concentration for porphyromonas gingivalis bacteria that is specific for Periodontitis Stage 3.
Drug: diode laser
Real time Pcr was used to detect gene concentration 16s specific for porphyromonas gingivalis
Experimental: Diode laser
Epic X 0.9watt device was used
Drug: Liquorice Nanogel
Real Time pcr was chosen to detect 16s gene concentration for porphyromonas gingivalis bacteria that is specific for Periodontitis Stage 3.
Drug: diode laser
Real time Pcr was used to detect gene concentration 16s specific for porphyromonas gingivalis

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Quantitative analysis using real time pcr
Time Frame: 3 months
3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Al-Azhar University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2024

Primary Completion (Actual)

September 28, 2025

Study Completion (Actual)

April 1, 2026

Study Registration Dates

First Submitted

May 12, 2026

First Submitted That Met QC Criteria

May 19, 2026

First Posted (Actual)

May 22, 2026

Study Record Updates

Last Update Posted (Actual)

May 22, 2026

Last Update Submitted That Met QC Criteria

May 19, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • P-ME-24-10

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe